Phase III trial activity for melanoma is robust: biologics being studied include CTLA4 blockers, apoptosis restorers, and antiangiogenesis ... An article from: Skin & Allergy News

This digital document is an article from Skin & Allergy News, published by Thomson Gale on September 1, 2007. The length of the article is 1145 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser.

Citation Details
Title: Phase III trial activity for melanoma is robust: biologics being studied include CTLA4 blockers, apoptosis restorers, and antiangiogenesis agents.(Cutaneous Oncology)
Author: Bruce Jancin
Publication:Skin & Allergy News (Magazine/Journal)
Date: September 1, 2007
Publisher: Thomson Gale
Volume: 38 Issue: 9 Page: 17(1)

Distributed by Thomson Gale